The SCORE project focuses on the development of coronavirus-specific therapeutics and will do so
● short-term, by developing combinations of repurposed drugs;
● mid-term, by expediting studies on compounds already in development;
● longer-term, by pursuing de novo discovery and development of inhibitors.
This multi-pace approach is warranted because it is unclear at the moment whether the current virus will spread to cause a full-blown pandemic and/or continue to circulate for a prolonged time. As exemplified by the prior SARS-CoV and MERS-CoV outbreaks, and the current SARS-CoV-2 epidemic, it is clearly only a matter of time until the next zoonotic coronavirus will appear on the world stage. Therefore, it is key to also invest in a longer-term effort with the purpose of developing novel, specific, and potent broad-spectrum inhibitors of coronavirus infection or replication.